FDA Handling Of Sanofi’s Ketek Is Latest Target Of Congressional Scrutiny
This article was originally published in Pharmaceutical Approvals Monthly
Senate Finance Committee Chairman Chuck Grassley has requested that senior Center for Drug Evaluation & Research staff brief committee staff on FDA's regulatory oversight of Sanofi-Aventis' antibiotic Ketek by May 18
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class